Biogen

Latest

Morphosys and the Biogen Development

There has recently been a setback at Biogen. At the beginning of the month, an FDA advisory committee was unimpressed…

Read More »
Latest

Biogen: A minus that is too high

On Friday, an FDA advisory committee rejected a majority of Biogen’s aducanumab. This is a potential Alzheimer’s drug. Only one…

Read More »
Back to top button
Close
Close